Published in Blood Weekly, September 25th, 1995
The compound to be tested, busulfan, is currently approved by the FDA for use in oral dose form, and marketed by another company, for treatment of chronic leukemia. However, it is also being used off-label by transplant physicians as preparative chemotherapy prior to bone-marrow transplants. Sparta Pharmaceuticals' busulfan formulation is an injectable, prepared with the company's proprietary Spartaject...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.